{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:07:40Z","timestamp":1793041660313,"version":"4.5.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","license":[{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) is a leading cause of chronic liver disease worldwide with decreased life expectancy. Duodenal mucosal resurfacing (DMR) has been associated with metabolic improvement in glycemic and hepatic parameters of type 2 diabetes, but the metabolic impact of DMR for NAFLD\/NASH remains inconclusive. We conducted a meta-analysis to investigate metabolic effects of DMR in patients with NAFLD\/NASH.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Three major bibliographic databases were reviewed for enrollment of trials prior to January 28, 2022. We included adults with biopsy-proven NAFLD\/NASH or liver magnetic resonance imaging proton density fat fraction (MRI-PDFF)\u2005&gt;5% at baseline and focused on the metabolic difference of MRI-PDFF at 12 weeks, and HbA1c or homeostatic model assessment index for insulin resistance (HOMA-IR) at 24 weeks.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Two studies involved a total of 67 participants for analysis. When compared with pre-intervention status, mean difference of MRI-PDFF, HbA1c, and HOMA-IR after DMR were \u22122.22 (95% CI: \u221212.79~8.34), \u22120.32% (95% CI: \u22120.80~0.16), and 0.15 (95% CI: \u22125.11~5.41) without statistical significance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>For patients with NAFLD\/NASH, DMR has the trend to improve liver fat at 12 weeks, and glycemic control in terms of HbA1c level at 24 weeks based on a very low quality of evidence.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000035147","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T12:06:40Z","timestamp":1696594000000},"page":"e35147","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["The metabolic influence of duodenal mucosal resurfacing for nonalcoholic fatty liver disease"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2729-5083","authenticated-orcid":false,"given":"Te-Jung","family":"Chuang","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tri Service General Hospital, Taipei, Taiwan"},{"name":"Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Wang","family":"Ko","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sz-Iuan","family":"Shiu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan"},{"name":"Department of Critical Care Medicine, Taichung Veterans General Hospital, Taichung, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/cld.1045","article-title":"Nonalcoholic fatty liver disease and recent guideline updates.","volume":"17","author":"Ando","year":"2021","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.","volume":"18","author":"Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(22)00078-X","article-title":"Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.","volume":"23","author":"Tan","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1 Suppl","key":"R6-20250504","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease.","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis.","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1007\/s10620-013-2743-5","article-title":"Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD).","volume":"58","author":"Stepanova","year":"2013","journal-title":"Dig Dis Sci"},{"key":"R9-20250504","first-page":"CD013156","article-title":"Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis.","volume":"6","author":"Buzzetti","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"R10-20250504","first-page":"CD013157","article-title":"Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis.","volume":"7","author":"Komolafe","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.16583","article-title":"Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH.","volume":"54","author":"Majzoub","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.cgh.2018.10.017","article-title":"Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis.","volume":"17","author":"Lee","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1007\/s11695-022-06011-1","article-title":"Bariatric surgery improves nonalcoholic fatty liver disease: systematic review and meta-analysis.","volume":"32","author":"Zhou","year":"2022","journal-title":"Obes Surg"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1007\/s00268-021-06382-z","article-title":"Bariatric surgery is effective and safe for obese patients with compensated cirrhosis: a systematic review and meta-analysis.","volume":"46","author":"Bai","year":"2022","journal-title":"World J Surg"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.soard.2022.03.011","article-title":"Outcomes of bariatric surgery in patients with obesity and compensated liver cirrhosis.","volume":"18","author":"Khajeh","year":"2022","journal-title":"Surg Obes Relat Dis"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.soard.2018.10.005","article-title":"Reasons for underutilization of bariatric surgery: the role of insurance benefit design.","volume":"15","author":"Gasoyan","year":"2019","journal-title":"Surg Obes Relat Dis"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/liv.14441","article-title":"Endoscopic bariatric and metabolic therapies for non-alcoholic fatty liver disease: evidence and perspectives.","volume":"40","author":"Salomone","year":"2020","journal-title":"Liver Int"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.gie.2019.03.024","article-title":"Duodenal mucosal resurfacing: proof-of-concept, procedural development, and initial implementation in the clinical setting.","volume":"90","author":"Haidry","year":"2019","journal-title":"Gastrointest Endosc"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1136\/gutjnl-2020-323608","article-title":"Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial.","volume":"71","author":"Mingrone","year":"2022","journal-title":"Gut"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1053\/j.gastro.2017.01.044","article-title":"Endoscopic bariatric and metabolic therapies: new and emerging technologies.","volume":"152","author":"Sullivan","year":"2017","journal-title":"Gastroenterology"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"880749","DOI":"10.3389\/fmed.2022.880749","article-title":"Endoscopic bariatric and metabolic therapies and their effects on metabolic syndrome and non-alcoholic fatty liver disease - A systematic review and meta-Analysis.","volume":"9","author":"Lee","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamasurg.2013.3654","article-title":"The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012.","volume":"149","author":"Chang","year":"2014","journal-title":"JAMA Surg"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/oby.21555","article-title":"Delayed gastric emptying as a proposed mechanism of action during intragastric balloon therapy: results of a prospective study.","volume":"24","author":"G\u00f3mez","year":"2016","journal-title":"Obesity (Silver Spring)"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s11695-012-0834-6","article-title":"Fasting and meal-induced CCK and PP secretion following intragastric balloon treatment for obesity.","volume":"23","author":"Mathus-Vliegen","year":"2013","journal-title":"Obes Surg"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.gie.2012.05.023","article-title":"Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study.","volume":"76","author":"Lee","year":"2012","journal-title":"Gastrointest Endosc"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.cgh.2020.04.068","article-title":"Intragastric balloon placement induces significant metabolic and histologic improvement in patients with nonalcoholic steatohepatitis.","volume":"19","author":"Bazerbachi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/oby.21702","article-title":"Randomized sham-controlled trial evaluating efficacy and safety of endoscopic gastric plication for primary obesity: the ESSENTIAL trial.","volume":"25","author":"Sullivan","year":"2017","journal-title":"Obesity (Silver Spring)"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.gie.2019.09.029","article-title":"Endoscopic sleeve gastroplasty versus high-intensity diet and lifestyle therapy: a case-matched study.","volume":"91","author":"Cheskin","year":"2020","journal-title":"Gastrointest Endosc"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.gie.2020.08.023","article-title":"Improvement in insulin resistance and estimated hepatic steatosis and fibrosis after endoscopic sleeve gastroplasty.","volume":"93","author":"Hajifathalian","year":"2021","journal-title":"Gastrointest Endosc"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s12664-021-01202-7","article-title":"Endoscopic sleeve gastroplasty - minimally invasive treatment for non-alcoholic fatty liver disease and obesity.","volume":"40","author":"Jagtap","year":"2021","journal-title":"Indian J Gastroenterol"},{"key":"R35-20250504","first-page":"116","article-title":"EndoBarrier gastrointestinal liner in type 2 diabetic patients improves liver fibrosis as assessed by liver elastography.","volume":"125","author":"Gollisch","year":"2017","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1007\/s11695-018-3441-3","article-title":"Adverse events of the Duodenal-Jejunal Bypass Liner: a systematic review.","volume":"28","author":"Betzel","year":"2018","journal-title":"Obes Surg"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/SLA.0000000000004339","article-title":"Efficacy and safety of the duodeno-jejunal bypass liner in patients with metabolic syndrome: a multicenter randomized controlled trial (ENDOMETAB).","volume":"272","author":"Caiazzo","year":"2020","journal-title":"Ann Surg"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s11892-015-0607-4","article-title":"Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms.","volume":"15","author":"Saponaro","year":"2015","journal-title":"Curr Diab Rep"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"E59","DOI":"10.1152\/ajpendo.00559.2012","article-title":"Nutrient infusion bypassing duodenum-jejunum improves insulin sensitivity in glucose-tolerant and diabetic obese subjects.","volume":"305","author":"Salinari","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/gutjnl-2019-318349","article-title":"Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one-year results from the first international, open-label, prospective, multicentre study.","volume":"69","author":"van Baar","year":"2020","journal-title":"Gut"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.gie.2020.12.021","article-title":"Duodenal mucosal resurfacing combined with glucagon-like peptide-1 receptor agonism to discontinue insulin in type 2 diabetes: a feasibility study.","volume":"94","author":"van Baar","year":"2021","journal-title":"Gastrointest Endosc"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s11695-020-05170-3","article-title":"Metabolic effects of endoscopic duodenal mucosal resurfacing: a systematic review and meta-analysis.","volume":"31","author":"de Oliveira","year":"2021","journal-title":"Obes Surg"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/S0618-8278(19)30124-0","article-title":"Endoscopic duodenal mucosal resurfacing improves hepatic fat fraction, glycemic and lipid profiles in type 2 diabetes.","volume":"70","author":"Aithal","year":"2019","journal-title":"J Hepatol"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"154908","DOI":"10.1016\/j.metabol.2021.154908","article-title":"Mechanisms of action of duodenal mucosal resurfacing in insulin resistant women with polycystic ovary syndrome.","volume":"125","author":"Kaur","year":"2021","journal-title":"Metabolism"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2021.04.044","article-title":"Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis.","volume":"75","author":"Selvaraj","year":"2021","journal-title":"J Hepatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:07:11Z","timestamp":1746328031000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,6]]},"references-count":45,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035147","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,6]]}}}